Articles tagged with Alzheimer Disease
Researchers found that vitamin D3 and omega-3 fatty acids improved the immune system's ability to clear amyloid plaques from the brain. The study identified key genes and signaling networks regulated by these substances, which may help control inflammation and improve plaque clearance.
Researchers have identified a key step in the Alzheimer's disease pathway that can be interrupted using green tea and red wine extracts. The study, published in the Journal of Biological Chemistry, offers potential new targets for developing drugs to treat the disease.
A new study reveals that amyloid peptides build-up in brain's blood vessels accelerates cognitive decline by limiting oxygen-rich blood and nutrients. Researchers identify CD36 as a key protein in the buildup of Aβ40 in blood vessels, promoting cerebral amyloid angiopathy (CAA).
A new Penn study found no evidence to support concerns that abnormal disease proteins are infectious and can be transmitted from one person to another. Researchers analyzed data from a cohort of patients who received human growth hormone therapy and found no cases of Alzheimer's, Parkinson's, or other neurodegenerative diseases.
A study published in JAMA Neurology found no evidence of human-to-human transmission of AD and PD protein in cadaver-derived hGH recipients, contradicting previous concerns. The research included 34 autopsy patients and a group of c-hGH recipients, yielding no cases of AD or PD.
Scientists found that people with type 2 diabetes face twice the risk of developing Alzheimer's disease due to peptide deposits. Researchers discovered the molecular interactions between amyloid beta and amylin peptides, which may lead to protein aggregation and disease progression.
Researchers at UNC School of Medicine found striking similarities between heart cells and brain cells in patients with Alzheimer's disease, suggesting a new treatment paradigm for heart failure. Misfolded proteins in heart cells are a key factor in the process of heart failure.
A study by Brown University researchers found that the protein apoE4 is surprisingly useful in promoting neuron growth, even though it's associated with Alzheimer's disease. The findings suggest a better method for growing neurons outside the body, which could be used to treat neurodegenerative diseases.
The Society of Nuclear Medicine and Molecular Imaging has published the first guidelines for brain amyloid imaging in Alzheimer's disease, providing a framework for healthcare practitioners to determine when to order this test. The guidelines emphasize that amyloid PET imaging should be used judiciously, particularly among elderly indi...
Researchers have developed a new technique to identify abnormal tau proteins associated with repetitive head injuries, potentially leading to earlier diagnosis and tracking of brain disorders. The study used PET scans to detect elevated levels of FDDNP in the brains of five retired NFL players.
Researchers at the University of Pennsylvania School of Medicine developed a new animal model that replicates the transmission of tau pathology, a hallmark of Alzheimer's disease. The study demonstrates that synthetic tau fibrils can induce authentic neurofibrillary tangles and initiate disease progression in mice.
Researchers at Université Laval have identified a molecule that stimulates the activity of the brain's immune cells, which could lead to a treatment and vaccine for Alzheimer's disease. Weekly injections of MPL eliminated up to 80% of senile plaques in mice with Alzheimer's symptoms, improving cognitive function.
A UCI study reveals that people with Down syndrome are more susceptible to other conditions due to a breakdown in energy metabolism within brain cells. This metabolic dysfunction contributes to the higher probability of Alzheimer's disease, diabetes and autistic spectrum disorders.
Researchers have demonstrated that obesity aggravates disorders associated with tau protein in mice, contradicting previous assumptions. The study suggests environmental factors contribute to the development of Alzheimer's disease, rather than just metabolic conditions.
A study published in Cerebral Cortex found that brain changes associated with common gene variants linked to disorders like Alzheimer's disease and schizophrenia can be seen in newborns. These findings suggest that prenatal brain development may play a significant role in shaping psychiatric risk later in life.
A new research report published in the FASEB Journal shows that TFP5, a small molecule, rescues plaques and tangles by blocking an overactive brain signal, restoring memory in mice with Alzheimer's. Clinical trial studies may yield extended quality of life for patients.
Depression in Medicare recipients over 65 is associated with prevalent mild cognitive impairment (MCI) and increased dementia risk. The study found that depression was related to higher MCI and dementia risks, as well as progression from MCI to dementia.
A new study shows that exposure to cosmic radiation in space can increase the risk of developing Alzheimer's disease. Researchers found that high-mass particles, like iron, can penetrate spacecraft shielding and cause neurological impairment in animal models.
Researchers found that people with mild cognitive impairment and Alzheimer's disease struggle to process semantic information, leading to broader implications for daily functioning. Semantic processing deficits may be slowed through training, and could contribute to decline in activities of daily living.
Researchers developed a new MRI method to predict the ratio of tau and beta-amyloid proteins in cerebrospinal fluid, achieving 75% accuracy in identifying correct diagnoses. The method could be used as a screening tool and help monitor biomarkers over time in clinical trials.
Researchers at the University of Pennsylvania developed a non-invasive MRI-based algorithm to screen patients for Alzheimer's disease or frontotemporal lobar degeneration. The method, published in Neurology, accurately differentiated cases 75 percent of the time and showed comparable accuracy to lumbar puncture tests.
A new study by the American Academy of Neurology reveals that people without a spouse are underrepresented in Alzheimer's disease clinical trials. The study found that participants with adult child partners were more likely to be from diverse backgrounds, while those with spouse partners were more likely to be white and older.
Scientists at the University of Bonn have identified a new signaling pathway involved in chronic inflammation, which contributes to nerve cell malfunctions and death. By deactivating key genes, they observed reduced inflammation, memory loss, and beta-amyloid peptide deposition in genetically modified mice.
Researchers have discovered a key link between inflammation and Alzheimer's disease progression. The study suggests that drugs targeting IL-1 beta production may provide benefits for patients with Alzheimer's. The findings point to the possibility of developing new treatments by disrupting the production of this pro-inflammatory cytokine.
Researchers found that non-spouse caregivers are less likely to participate in Alzheimer's clinical trials, citing higher dropout rates and adverse events. The study highlights the need for tailored recruitment efforts to increase enrollment of patients with diverse caregiver arrangements.
Researchers have found that blocking the NLRP3 inflammasome can prevent Alzheimer's disease. The study, which involved human and mouse subjects, suggests that suppressing inflammatory reactions may be a promising new approach to therapy.
A new UCLA study assesses the prevalence of various study partner types in Alzheimer's clinical trials, finding that non-spouse partners can impact trial results and interpretations. The study also highlights disparities in recruitment among minority groups.
Researchers discovered that Alzheimer's disease is caused by faulty cell cycle control in neurons, triggered by the combination of amyloid-beta and tau proteins. In normal cells, these proteins do not induce cell cycle re-entry, but in AD neurons, they do, leading to cell death.
A new study suggests that rapid law enforcement notification and detailed public information can improve recovery rates for drivers with dementia. The research team recommends that Silver Alert-type programs prioritize the cognitive status of drivers and provide more detailed information to facilitate rescue efforts.
A combination of diagnostic tests, including MRI, PET and cerebrospinal fluid biomarkers, can improve the prediction of conversion from mild cognitive impairment to Alzheimer's disease. The study found that combining these tests reduced false classifications and increased accuracy compared to clinical testing alone.
Researchers at the University of Alberta have discovered a potential treatment for Alzheimer's disease, finding that a diabetes drug can restore memory in brain cells. The team tested the drug on animal models with Alzheimer's and found significant improvements in memory function.
Researchers at Duke University Medical Center found that combining diagnostic tests more accurately predicts Alzheimer's in patients with mild cognitive impairment. The combination of MRI, FDG-PET, and cerebrospinal fluid analysis reduced misdiagnoses by 28.4% compared to individual tests.
People who experienced hunger as children had slower cognitive decline than those who never went hungry, with African American participants showing a significant protective effect. The study suggests calorie restriction or selective survival effects may be responsible for this finding.
Gladstone researchers propose targeting ApoE4 as a new strategy for treating Alzheimer's disease. They suggest that drugs can correct the shape of the ApoE4 protein, slowing or stopping its progression.
Researchers at Johns Hopkins Medicine have successfully implanted a pacemaker-like device in the brain of an Alzheimer's disease patient, marking the first such operation in the US. The device aims to boost memory and reverse cognitive decline by providing deep brain stimulation.
Researchers developed a plaque-specific antibody that clears existing β-amyloid deposits in Alzheimer's disease mice, promoting potential treatment development. The study suggests that targeting insoluble amyloid beta is critical for plaque removal without microhemorrhage side effects.
Scientists have developed a transgenic zebrafish model, MitoFish, that enables non-invasive observation of mitochondria transport in living neurons, providing a new window into neurodegenerative diseases such as Alzheimer's and Parkinson's. This breakthrough model has the potential to accelerate the search for effective treatments.
Scientists from VIB and KU Leuven discovered a new target molecule to develop a treatment against Alzheimer's disease. β-arrestin 2 plays a role in regulating the γ-secretase complex function and development of the disease. This research opens a new avenue for treating the disease at an early stage.
Researchers at the University of Minnesota's Center for Drug Design developed a synthetic compound, psi-GSH, that prevents neurodegeneration associated with Alzheimer's disease in a mouse model. The compound enables the brain to use its own protective enzyme system against the disease process.
GSK3-beta activates BACE1, producing amyloid beta that forms plaques, killing neural cells. Disabling GSK3-beta reduces plaque formation and improves memory in mice. A promising target for AD drug research, but its indiscriminate effects pose challenges.
Researchers at Rensselaer Polytechnic Institute have created novel antibodies that can prevent the formation of toxic protein particles linked to diseases such as Alzheimer's and Parkinson's. These antibodies bind to 10 proteins per molecule, making them more potent inhibitors than conventional antibodies.
Researchers have developed a new treatment approach for Alzheimer's disease by knocking out the gene responsible for producing the HDAC6 enzyme. This intervention improved cognitive abilities and behavioral disorders in mice, suggesting that improving cellular traffic may be key to treating neurodegenerative diseases.
A study published in Alzheimer Disease & Associated Disorders found that a florbetapir PET scan can alter physicians' diagnostic thinking, guiding treatment and further testing for patients with cognitive impairment. The test showed amyloid deposits in 113 out of 229 patients, leading to changes in diagnosis and treatment plans.
A study found that women with Alzheimer's disease exhibit greater gray matter loss in the brain compared to men, with differences observed in regional atrophy patterns. This discovery has important implications for the development of therapies for mild cognitive impairment and Alzheimer's disease.
A study found that an active lifestyle can preserve gray matter in older adults' brains, reducing the burden of dementia and Alzheimer's disease. The research suggests that a combination of lifestyle choices, including aerobic physical activities, may alleviate brain aging.
Researchers from University of Zurich found turning off specific cytokines reduces Alzheimer's amyloid-ß deposits by 65% in mice. Behavioral testing showed substantial improvements when p40 molecule-blocking antibody was administered, suggesting potential human therapy.
Researchers have identified a molecular pathway driving Alzheimer's disease progression, revealing new targets for drug discovery. The study found that clusterin acts to switch on a signalling pathway associated with tau tangle formation and cognitive defects.
A diabetes drug initially used to treat insulin resistance has shown promise in improving cognitive performance in some people with Alzheimer's disease. Researchers found that rosiglitazone enhanced learning and memory while normalizing insulin resistance by reducing the negative influence of Alzheimer's on brain-signaling molecules.
A new factor of genetic susceptibility to Alzheimer's disease has been identified through a large-scale international study. Mutations in the TREM2 gene on chromosome 6 are associated with a five times greater risk of developing late-onset Alzheimer's disease, according to researchers.
Researchers discovered an organic compound, D737, that restored motor function and longevity to fruit flies with Alzheimer's disease. The compound prevented protein clumps, a hallmark of the disease, by inhibiting amyloid beta 42 aggregation.
Researchers at UCLA have developed a molecular compound called CLR01 that breaks up toxic protein aggregations in a mouse model, clearing amyloid-beta and tau aggregates and protecting neurons' synapses. The compound has shown high safety and efficacy in treating Alzheimer's disease.
Researchers discovered a genetic mutation in the TREM2 gene linked to increased Alzheimer's disease risk. The study found that this rare mutation occurs in just 0.3% of the population but makes patients three times more likely to develop the disease.
A gene variant known as R47H in TREM2 nearly triples the risk of Alzheimer's disease, according to a global team including Mayo Clinic researchers. The study identified rare variants in TREM2 associated with an increased risk of Alzheimer's, with the R47H variant showing strong association with the disease.
A team of researchers from Nottingham University has discovered a rare genetic variant associated with an increased risk of Alzheimer's disease. The study, which used data from over 25,000 people, found that a specific mutation in the TREM2 gene may play a key role in the development of the disease.
Researchers at LSU Health Sciences Center have identified Monoacylglycerol lipase (MAGL) as a promising therapeutic target for treating or preventing Alzheimer's disease. Inactivation of MAGL reduced beta amyloid plaque production and improved brain function, learning, and memory.
Researchers at Salk Institute discover diabetes increases amyloid beta and tau protein levels, leading to accelerated brain aging. The study suggests the neurovascular system as a potential therapeutic target for early-stage Alzheimer's treatment.
Researchers at The Mount Sinai School of Medicine presented a study demonstrating IRX4204's ability to alleviate cognitive decline in animal models of Alzheimer's disease. The compound also prevents neuropathological features associated with abnormal tau processing, a common feature of Parkinson's disease with dementia.
A Mayo Clinic study found that a gene linked to Alzheimer's, heart disease, and diabetes becomes less important to quality of life once people reach their 90s. Researchers discovered that good friends, a positive attitude, and social connectedness have a bigger impact on well-being than the gene in question.
A new study suggests that hormone therapy initiated close to menopause can reduce the risk of developing Alzheimer's disease. Women who began hormone therapy within five years of menopause had a 30% lower risk of Alzheimer's dementia than those who did not use hormone therapy.
A study has found a key difference between brains of people with Alzheimer's disease and those who are cognitively normal but have brain plaques. Researchers detected smaller molecules of amyloid beta called oligomers, which were more closely correlated with dementia symptoms.